Nature Reviews Drug Discovery

Neutrophil-targeting drug seeks first approval in an inflammatory lung disease

Katie Kingwell Jul 01, 2025 pp. 487-489 10.1038/d41573-025-00108-9

Upcoming FDA approval decisions in Q3 2025

Andrew Shui-Jezierski Jul 01, 2025 pp. 494-494 10.1038/d41573-025-00103-0

Keeping the immuno-oncology flame burning

Asher Mullard Jul 01, 2025 pp. 495-497 10.1038/d41573-025-00107-w

FDA approves a c-MET-targeted ADC for lung cancer

Asher Mullard Jul 01, 2025 pp. 490-490 10.1038/d41573-025-00104-z

FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease

Asher Mullard Jul 01, 2025 pp. 491-491 10.1038/d41573-025-00106-x

PD1 × VEGF blocking bispecifics for cancer draw big backing

Asher Mullard Jul 01, 2025 pp. 490-490 10.1038/d41573-025-00105-y

Cryptic antigens flag cancer cells to T cell therapy

Katie Kingwell Jul 01, 2025 pp. 500-500 10.1038/d41573-025-00099-7

In utero ASO therapy for spinal muscular atrophy

M. Teresa Villanueva Jul 01, 2025 pp. 502-502 10.1038/d41573-025-00097-9

Blocking a cell surface protein beats AML

Sarah Crunkhorn Jul 01, 2025 pp. 503-503 10.1038/d41573-025-00095-x

Lowering pathological α-synuclein

Sarah Crunkhorn Jul 01, 2025 pp. 503-503 10.1038/d41573-025-00093-z

Prolonging the antidepressant effects of ketamine

Sarah Crunkhorn Jul 01, 2025 pp. 503-503 10.1038/d41573-025-00094-y

Towards a universal snake antivenom

Sarah Crunkhorn Jul 01, 2025 pp. 503-503 10.1038/d41573-025-00092-0

A new drug target for NRAS(Q61) mutant-expressing cancers

Katharine H. Wrighton Jul 01, 2025 pp. 502-502 10.1038/d41573-025-00091-1

Author Correction: GLP-1-based therapies for diabetes, obesity and beyond

Daniel J. Drucker Jul 01, 2025 pp. 570-570 10.1038/s41573-025-01231-3

Triggering ferroptosis in drug-tolerant cancer cells

Sarah Crunkhorn Jul 01, 2025 pp. 501-501 10.1038/d41573-025-00090-2

The race to reset autoimmune diseases

Mayank Bhandari, Jeffrey F. Smith, Emily Capra et al. Jul 01, 2025 pp. 498-499 10.1038/d41573-025-00085-z

The impact of accelerated drug marketing registration procedures on the review and approval of new drugs in China

Yingge Gu, Ran Jing, Kenneth I. Kaitin et al. Jul 01, 2025 pp. 492-493 10.1038/d41573-025-00070-6

Fibrosis: cross-organ biology and pathways to development of innovative drugs

Florian Rieder, Laura E. Nagy, Toby M. Maher et al. Jul 01, 2025 pp. 543-569 10.1038/s41573-025-01158-9

Computational drug repurposing: approaches, evaluation of in silico resources and case studies

Ziaurrehman Tanoli, Adrià Fernández-Torras, Umut Onur Özcan et al. Jul 01, 2025 pp. 521-542 10.1038/s41573-025-01164-x

Tumour-agnostic kinase inhibitors

Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock Jul 01, 2025 pp. 504-520 10.1038/s41573-025-01147-y

A new European platform for advancing regulatory science research

Liese Barbier, Pierpaolo Moscariello, Hubert G Leufkens et al. Jul 01, 2025 pp. 485-486 10.1038/d41573-025-00024-y